MHRA paediatric investigation plan
HEPLISAV B (Hepatitis B (rDNA) surface antigen adjuvanted)
MHRA paediatric investigation plan MHRA-100557-PIP01-22-M01 (update) · Modification
Key facts
| PIP number | MHRA-100557-PIP01-22-M01 (update) |
|---|---|
| Product names | HEPLISAV B, HEPLISAV-B |
| Active substances | Hepatitis B (rDNA) surface antigen adjuvanted |
| Therapeutic areas | Vaccines |
| Conditions | Prevention of hepatitis B virus infection |
| Decision | PM: decision on the application for modification of an agreed paediatric investigation plan. |
| Published | Dec 7, 2022 |
| MHRA record | cms.mhra.gov.uk |
About MHRA paediatric investigation plans
A paediatric investigation plan sets out the studies a company must run in children to support authorisation of a medicine in the UK, or records a waiver or deferral.
Source: UK Medicines and Healthcare products Regulatory Agency (MHRA). Contains public sector information licensed under the Open Government Licence v3.0 · Source date: